Pharmacokinetic-Pharmacodynamic Relationship of Levodopa with and without Tolcapone in Patients with Parkinson??s Disease
- 1 January 2001
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Clinical Pharmacokinetics
- Vol. 40 (5), 383-393
- https://doi.org/10.2165/00003088-200140050-00005
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patientsMovement Disorders, 1998
- LEVODOPA AND 3-O-METHYLDOPA IN CEREBROSPINAL FLUID AFTER LEVODOPA-CARBIDOPA ASSOCIATIONPharmacological Research, 1997
- Effects of Catechol-O-methyltransferase Inhibition on the Rates of Uptake and Reversibility of 6-Fluoro-l-Dopa Trapping in MPTP-induced Parkinsonism in MonkeysNeuropharmacology, 1997
- Pharmacokinetic Optimisation in the Treatment of Parkinson's DiseaseClinical Pharmacokinetics, 1996
- Concentration-Effect Relationship of Levodopa in Patients with Parkinson's DiseaseClinical Pharmacokinetics, 1995
- 3‐O‐methyldopa administration does not alter fluorodopa transport into the brainAnnals of Neurology, 1992
- Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.Journal of Neurology, Neurosurgery & Psychiatry, 1992
- Clinical Pharmacokinetics of Anti-Parkinsonian DrugsClinical Pharmacokinetics, 1987
- 3‐O‐Methyldopa and the response to levodopa in Parkinson's diseaseAnnals of Neurology, 1987
- ParkinsonismNeurology, 1967